Latest Stock Market News

Motilal Oswal: Capital expenditure-linked stocks extended losses on Monday after Saturday’s sharp decline. Larsen & Toubro fell 4.6% to ₹3,287.25, IRB Infra dropped over 4.6%, and Siemens slid 9%. Motilal Oswal attributed the decline to the government’s FY25 capex cut to Rs 10.2 lakh crore and a modest 10% growth forecast for FY26, down from 30% annually in FY21-FY24.

Acme Solar: Acme Solar Holdings surged 19% in four sessions after strong Q3 results. The company nearly doubled operational capacity, reduced debt via IPO proceeds, and targets 10 GW renewable capacity by 2030 while improving efficiency and power purchase agreements.

Entities behind President Donald Trump s crypto coin have accumulated close to $100 million in trading fees in less than two weeks, according to estimates from three blockchain analysis firms, a large windfall from a venture that has seen tens of thousands of small traders lose money.

Gold prices jumped Rs 400 to hit a fresh record high of Rs 85,300 per 10 grams in the national capital on Monday on the back of continued demand by jewellers and stockists, according to the All India Sarafa Association. Traders said sharp depreciation in rupee and firm trends in the international markets lifted gold rates to record high levels.

Indian markets closed lower on Monday due to weak global cues. Sensex fell over 300 points, while Nifty50 stayed above 23,300. Healthcare, IT, and consumer durables gained, while utilities, PSU, and power stocks declined.

Veeda Clinical Research: Veeda Clinical Research has refiled its IPO papers with SEBI, planning to raise funds through a fresh issue and offer-for-sale. The proceeds will support capital expenditure, subsidiary investments, debt repayment, and business growth. The IPO will follow a book-building process.

Indian markets fell as Trump s tariffs and budget disappointments hit sentiment. Nifty dropped 0.52%, Sensex fell 0.41%. Swiggy gained 5%, UPL rose 4.22%, HUDCO plunged 8.90%, Vedanta dropped 3.96%, and L&T declined 4.69%.

Clinical research organisation Veeda Clinical Research has re-filed preliminary papers with markets regulator Sebi seeking its approval to raise funds through an initial share sale.

When promoters increase their stakes in a company, it’s seen as a positive sign, indicating their confidence in its growth potential and future stock performance.